Guarana for Health & Longevity - Quick Reference Sheet

Guarana for Health & Longevity

Created on 09/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Guarana, an Amazonian seed used for energy and focus, is mainly a caffeine source, not a distinct longevity tool. Its most consistent effect is a small, short-lived gain in reaction speed and alertness after a single serving, plus modest gains in some endurance tasks. Main risks are caffeine's: poorer sleep, restlessness, higher blood pressure, dependence and harm during pregnancy. Caffeine content varies widely between products. No human lifespan studies exist. (Full Review)

Protocol

Cognitive protocol (Northumbria University group)
37.5–75 mg standardized extract
Single dose about 60 minutes before demanding work; lower doses outperformed 150–300 mg
Pre-exercise protocol
500 mg extract or 3 g seed powder
About 130 mg caffeine (extract); 60 minutes before endurance or intermittent exercise
Time of day
Morning to early afternoon
At least 8–9 hours before bedtime; a single morning dose suits most uses
Time to effect
Attention & reaction speed
30–60 minutes
Alertness rises after a single dose; effects lasted up to 6 hours in cognitive trials
Exercise output
About 60 minutes
Taken about an hour before endurance or intermittent exercise
Cancer-related fatigue
21 days
Fatigue trials assessed results after 21 days of daily use; benefit unproven

Benefits

Contraindications
  • Pregnancy, attempting conception, or breastfeeding (total caffeine usually capped at 200 mg/day)
  • Uncontrolled hypertension (at or above 160/100 mmHg, or above 140/90 mmHg despite treatment)
  • Heart rhythm disorders: atrial fibrillation, long QT syndrome (corrected QT above 470 milliseconds), Wolff-Parkinson-White syndrome, or recent heart attack (<90 days)
  • Panic disorder or poorly controlled anxiety disorders
  • Chronic insomnia
  • Advanced liver disease (Child-Pugh Class B or C)
  • Children and adolescents under 18
  • Poorly controlled seizure disorders
  • Cardiac stress-test agents (adenosine, regadenoson, dipyridamole) before testing (at least 24 hours)
Key Interactions
  • CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, cimetidine)
  • Estrogen-containing contraceptives and hormone therapy (ethinyl estradiol)
  • Stimulant medications (amphetamine, methylphenidate, modafinil)
  • Theophylline and aminophylline
  • Clozapine and olanzapine
  • Antihypertensive medications (amlodipine, lisinopril, metoprolol)
  • Lithium
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline)
  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, warfarin; theoretical)
  • Over-the-counter decongestants and caffeine-containing pain relievers (pseudoephedrine, phenylephrine, Excedrin)
  • Stimulant supplements (bitter orange/synephrine, yerba mate, kola nut, green tea extract, yohimbe)
  • Alcohol
  • Coffee, tea, energy drinks and chocolate

Risk & Side Effects

  • High: Sleep disruption; nervousness, anxiety, rapid heartbeat, gastrointestinal discomfort and headache; blood pressure elevation; dependence and withdrawal symptoms
  • Medium: Adverse pregnancy outcomes
  • Low: Serious heart rhythm disturbances and seizures with concentrated products; transient rise in blood sugar
  • Speculative: Increased bleeding tendency; reduced iron absorption; mouth and throat cancer with heavy tannin intake

Monitoring

Marker Target Why
Blood pressure (home, seated) 110–120 / 70–80 mmHg Caffeine raises it
Resting heart rate 50–70 bpm Detects stimulant-driven rapid heartbeat
Electrocardiogram Normal heart rhythm; QTc <450 ms (men), <460 ms (women) Screens for rhythm disorders caffeine can unmask
Total sleep time (wearable or diary) ≥7 hours per night; sleep efficiency ≥85% Detects caffeine-related sleep loss
Fasting glucose 75–90 mg/dL Tracks metabolic effects; caffeine can transiently raise glucose
HbA1c <5.4% Longer-term blood sugar marker
LDL cholesterol <100 mg/dL (many longevity clinicians target <70) Tracks the observational cholesterol association
Ferritin 50–150 ng/mL Monitors iron stores given theoretical tannin-iron binding

Cadence: Blood pressure and heart rate before and one hour after dosing during the first two weeks; sleep data review at 2 weeks and 3 months; blood work every 6–12 months

Qualitative Assessment

  • Daytime energy and alertness, including any afternoon slump
  • Sleep onset time and subjective sleep quality
  • Nervousness, restlessness or anxiety after dosing
  • Palpitations or awareness of heartbeat
  • Stomach comfort
  • Perceived effort during workouts
  • Headaches or low mood on missed days, signaling dependence